Ajouter à une liste

Communiqués Molecure S.A.

Actions

MOC

PLONCTH00011

Recherche biotechnologique et médicale

Marché Fermé - Warsaw S.E. 17:55:49 24/08/2026			Varia. 5j.	Varia. 1 janv.
6,140 ^PLN	-0,49%		-0,49%	-6,97%

03/08	Molecure reçoit une recommandation positive de l'IDMC pour poursuivre l'essai clinique KITE sans modification du protocole	CI
19/05	Molecure : perte nette de 4.1 millions de zlotys au premier trimestre	RE

Communiqués

04/08	Molecure reçoit une recommandation favorable de l’IDMC pour poursuivre l’essai clinique KITE sans modification du protocole de l’étude (programme de développement OATD-01)	GL
03/08	Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)	GL
31/07/24	Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs	BU
06/12/22	Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022	AQ
25/03/22	OncoArendi Therapeutics reports continued dynamic growth in 2021	AQ
15/03/22	OncoArendi - Announcement of the results of procedure No. 1/2022, DUBs	AQ
14/03/22	OncoArendi Therapeutics has entered into an exclusive license option agreement with the University of Michigan	AQ
03/03/22	OncoArendi Therapeutics - INVITATION TO TENDER NO 7/2022-DUBs - Successive delivery of selected cytokines	AQ
09/02/22	OncoArendi Therapeutics - Announcement of the results of procedure No. 46/2021, DUBs	AQ
08/02/22	OncoArendi Therapeutics is significantly moving closer to the start of a phase one clinical trial for OATD-02	AQ
01/02/22	OncoArendi Therapeutics Appoints Dr. Adam Gobiowski, Dr. Zbigniew Zasona and Agnieszka Rajczuk-Szczepaska to its Management Board	AQ
28/01/22	OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer	AQ
17/01/22	OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts, Nancy Van Osselaer, Paul van der Horst and Rafal Kamiski as its new members	AQ
29/11/21	OncoArendi Therapeutics - Announcement of the result of tender procedure No. 34/2021-DUBs	AQ
23/11/21	OncoArendi Therapeutics has opened a modern R&D laboratory	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Dès maintenant, trouvez facilement les meilleurs investissements de demain !